title: Localization of distinct F2-isoprostanes in human atherosclerotic lesions.
abstract: F2-Isoprostanes are prostaglandin (PG) isomers formed in situ in cell membranes by peroxidation of arachidonic acid. 8-epi PGF2alpha and IPF2alpha-I are F2-isoprostanes produced in humans which circulate in plasma and are excreted in urine. Measurement of F2-isoprostanes may offer a sensitive, specific, and noninvasive method for measuring oxidant stress in clinical settings where reactive oxygen species are putatively involved. We determined whether isoprostanes were present in human atherosclerotic lesions, where lipid peroxidation is thought to occur in vivo. 8-epi PGF2alpha ranged from 1.310-3.450 pmol/micromol phospholipid in atherectomy specimens compared with 0.045-0.115 pmol/micromol phospholipid (P < 0.001) in vascular tissue devoid of atherosclerosis. Corresponding values of IPF2alpha-I were 5.6-13.8 vs. 0.16-0.44 pmol/micromol phospholipid (P < 0.001). Levels of the two isoprostanes in vascular tissue were highly correlated (r = 0.80, P < 0.0001). Immunohistochemical studies confirmed that foam cells adjacent to the lipid necrotic core of the plaque were markedly positive for 8-epi PGF2alpha. These cells were also reactive with anti-CD68, an epitope specific for human monocyte/macrophages. 8-epi PGF2alpha immunoreactivity was also detected in cells positive for anti-alpha-smooth muscle actin antibody, which specifically recognizes vascular smooth muscle cells. Our results indicate that 8-epi PGF2alpha and IPF2alpha-I, two distinct F2-isoprostanes and markers of oxidative stress in vivo, are present in human atherosclerotic plaque. Quantitation of these chemically stable products of lipid peroxidation in target tissues, as well as in biological fluids, may aid in the rational development of antioxidant drugs in humans.
authors.affiliation: The Center for Experimental Therapeutics, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA.
authors.forename: D
authors.initials: D
authors.lastname: Praticò
authors.forename: L
authors.initials: L
authors.lastname: Iuliano
authors.forename: A
authors.initials: A
authors.lastname: Mauriello
authors.forename: L
authors.initials: L
authors.lastname: Spagnoli
authors.forename: J A
authors.initials: JA
authors.lastname: Lawson
authors.forename: J
authors.initials: J
authors.lastname: Rokach
authors.forename: J
authors.initials: J
authors.lastname: Maclouf
authors.forename: F
authors.initials: F
authors.lastname: Violi
authors.forename: G A
authors.initials: GA
authors.lastname: FitzGerald
mesh_terms: D000328:Adult; D000368:Aged; D015703:Antigens, CD / Q000032:analysis; D015214:Antigens, Differentiation, Myelomonocytic / Q000032:analysis; D001011:Aorta / Q000737:chemistry / Q000473:pathology; D001158:Arteries / Q000737:chemistry* / Q000473:pathology; D001161:Arteriosclerosis; D002339:Carotid Arteries / Q000737:chemistry / Q000473:pathology; D015237:Dinoprost / Q000031:analogs & derivatives* / Q000032:analysis; D005487:Foam Cells / Q000737:chemistry; D006801:Humans; D007536:Isomerism; D015227:Lipid Peroxidation; D008297:Male; D008875:Middle Aged; D018384:Oxidative Stress; D010743:Phospholipids / Q000032:analysis; D011651:Pulmonary Artery / Q000737:chemistry / Q000473:pathology; D000097382:CD68 Molecule
chemical_list: D015703:Antigens, CD; D015214:Antigens, Differentiation, Myelomonocytic; D015237:Dinoprost; D010743:Phospholipids; C067980:CD68 antigen, human; D000097382:CD68 Molecule; C075750:8-epi-prostaglandin F2alpha